Literature DB >> 3581417

Hepatic extraction, metabolism and biliary excretion of doxorubicin in the isolated perfused rat liver.

F Ballet, P Vrignaud, J Robert, C Rey, R Poupon.   

Abstract

The hepatic extraction, metabolism, and biliary excretion of doxorubicin (DX) were studied in the isolated perfused rat liver. Three doses of DX equivalent to 2, 20, and 100 mg/kg in rats were studied over a period of 3 h after bolus injection into the reservoir. DX and metabolites concentration in perfusate, bile, and liver were determined by high-pressure liquid chromatography. The hepatic extraction ratio was low (less than 0.24) and decreased progressively over the 3 h. The hepatic extraction and clearance were significantly lower at the highest dose. Doxorubicinol (DX-OL) was the only metabolite detected in the perfusate, accounting for less than 4% of the total AUC. Thirty-one to thirty-three percent of the dose was excreted into bile over 3 h as unchanged DX. This was reduced to 22% at the highest dose. Only 0.35%-1.33% of the dose was excreted as DX-OL. DX aglycones were found only in the liver, where they represented 20%-30% of the total fluorescence at 3 h. In conclusion, in this model DX has a low extraction ratio, is poorly metabolized and extensively excreted into bile.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3581417     DOI: 10.1007/bf00252979

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  23 in total

1.  Pharmacokinetics and metabolism of adriamycin in man.

Authors:  R S Benjamin; C E Riggs; N R Bachur
Journal:  Clin Pharmacol Ther       Date:  1973 Jul-Aug       Impact factor: 6.875

2.  Evidence of possible dose-dependent doxorubicin plasma kinetics in man.

Authors:  R C Boston; D R Phillips
Journal:  Cancer Treat Rep       Date:  1983-01

3.  Altered hepatic disposition of doxorubicin in the perfused rat liver at hyperthermic temperatures.

Authors:  J L Skibba; F E Jones; R E Condon
Journal:  Cancer Treat Rep       Date:  1982-06

Review 4.  The anthracycline antineoplastic drugs.

Authors:  R C Young; R F Ozols; C E Myers
Journal:  N Engl J Med       Date:  1981-07-16       Impact factor: 91.245

Review 5.  Dose-dependent pharmacokinetics and cancer chemotherapy.

Authors:  G Powis; M M Ames; J S Kovach
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

6.  The physiologic basis for clearance measurements in hepatology.

Authors:  K Winkler; L Bass; S Keiding; N Tygstrup
Journal:  Scand J Gastroenterol       Date:  1979       Impact factor: 2.423

7.  Hepatic extraction of adriamycin in patients with hepatocellular carcinoma.

Authors:  F Ballet; J C Barbare; R Poupon
Journal:  Eur J Cancer Clin Oncol       Date:  1984-06

8.  Effect of cyclophosphamide pretreatment on the short-term disposition and biliary excretion of adriamycin metabolites in rat.

Authors:  N Hartman; P J Basseches; G Powis
Journal:  Cancer Chemother Pharmacol       Date:  1982-12       Impact factor: 3.333

9.  Metabolic disposition of N,N-dibenzyldaunorubicin in the rat.

Authors:  J H Peters; G R Gordon; D Kashiwase; E M Acton; C A Hunt
Journal:  Cancer Res       Date:  1983-04       Impact factor: 12.701

10.  Cellular uptake and metabolism of daunorubicin as determined by high-performance liquid chromatography. Application to L1210 cells.

Authors:  R Baurain; A Zenebergh; A Trouet
Journal:  J Chromatogr       Date:  1978-09-21
View more
  10 in total

Review 1.  Role of P-glycoprotein in pharmacokinetics: clinical implications.

Authors:  Jiunn H Lin; Masayo Yamazaki
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Chronopharmacokinetics of doxorubicin in patients with breast cancer.

Authors:  P Canal; A Sqall; M de Forni; C Chevreau; A Pujol; R Bugat; H Roche; J Oustrin; G Houin
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  A probable relationship between characteristic accumulation of doxorubicin and P-glycoprotein transporter in rat liver.

Authors:  Kunio Fujiwara; Masashi Shin; Tsubasa Miyazaki
Journal:  J Mol Histol       Date:  2011-08-06       Impact factor: 2.611

4.  Intestinal bacteria are necessary for doxorubicin-induced intestinal damage but not for doxorubicin-induced apoptosis.

Authors:  Rachael J Rigby; Jacquelyn Carr; Kelly Orgel; Stephanie L King; P Kay Lund; Christopher M Dekaney
Journal:  Gut Microbes       Date:  2016-07-26

5.  Complete hepatic venous isolation and extracorporeal chemofiltration as treatment for human hepatocellular carcinoma: a phase I study.

Authors:  S A Curley; R A Newman; T B Dougherty; G M Fuhrman; D L Stone; J A Mikolajek; S Guercio; A Guercio; C H Carrasco; M T Kuo
Journal:  Ann Surg Oncol       Date:  1994-09       Impact factor: 5.344

6.  In vitro and in vivo evaluations of increased effective beam width for heat deposition using a split focus high intensity ultrasound (HIFU) transducer.

Authors:  Pretesh R Patel; Alfred Luk; Amirk Durrani; Sergio Dromi; Julian Cuesta; Mary Angstadt; Matthew R Dreher; Bradford J Wood; Victor Frenkel
Journal:  Int J Hyperthermia       Date:  2008-11       Impact factor: 3.914

7.  Increased doxorubicin levels in hepatic tumors with reduced systemic drug exposure achieved with complete hepatic venous isolation and extracorporeal chemofiltration.

Authors:  S A Curley; D L Stone; G M Fuhrman; D C Hohn; Z H Siddik; R A Newman
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  The Efficacy of Amifostine against Multiple-Dose Doxorubicin-Induced Toxicity in Rats.

Authors:  Vesna Jaćević; Viktorija Dragojević-Simić; Željka Tatomirović; Silva Dobrić; Dubravko Bokonjić; Aleksandra Kovačević; Eugenie Nepovimova; Martin Vališ; Kamil Kuča
Journal:  Int J Mol Sci       Date:  2018-08-12       Impact factor: 5.923

9.  Effects of Phytochemical P-Glycoprotein Modulators on the Pharmacokinetics and Tissue Distribution of Doxorubicin in Mice.

Authors:  Tae Hwan Kim; Soyoung Shin; Sun Dong Yoo; Beom Soo Shin
Journal:  Molecules       Date:  2018-02-07       Impact factor: 4.411

10.  Doxorubicin metabolism moderately attributes to putative toxicity in prodigiosin/doxorubicin synergism in vitro cells.

Authors:  Shian-Ren Lin; Chun-Shu Lin; Ching-Cheng Chen; Feng-Jen Tseng; Tsung-Jui Wu; Lebin Weng; Ching-Feng Weng
Journal:  Mol Cell Biochem       Date:  2020-08-04       Impact factor: 3.396

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.